RXL vs. BIB
Compare and contrast key facts about ProShares Ultra Health Care (RXL) and ProShares Ultra Nasdaq Biotechnology (BIB).
RXL and BIB are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. RXL is a passively managed fund by ProShares that tracks the performance of the Dow Jones U.S. Health Care Index (200%). It was launched on Jan 30, 2007. BIB is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (200%). It was launched on Apr 7, 2010. Both RXL and BIB are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Performance
RXL vs. BIB - Performance Comparison
Loading graphics...
RXL vs. BIB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
RXL ProShares Ultra Health Care | -9.67% | 19.76% | -2.72% | -3.15% | -15.26% | 48.06% | 19.24% | 40.40% | 3.38% | 46.92% |
BIB ProShares Ultra Nasdaq Biotechnology | 3.51% | 59.21% | -9.84% | -1.06% | -28.85% | -6.02% | 39.79% | 46.71% | -24.93% | 40.49% |
Returns By Period
In the year-to-date period, RXL achieves a -9.67% return, which is significantly lower than BIB's 3.51% return. Over the past 10 years, RXL has outperformed BIB with an annualized return of 12.77%, while BIB has yielded a comparatively lower 6.98% annualized return.
RXL
- 1D
- 1.75%
- 1M
- -12.90%
- YTD
- -9.67%
- 6M
- 4.12%
- 1Y
- 0.69%
- 3Y*
- 4.08%
- 5Y*
- 4.05%
- 10Y*
- 12.77%
BIB
- 1D
- 1.31%
- 1M
- -5.43%
- YTD
- 3.51%
- 6M
- 32.05%
- 1Y
- 82.75%
- 3Y*
- 16.12%
- 5Y*
- 0.02%
- 10Y*
- 6.98%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
RXL vs. BIB - Expense Ratio Comparison
Both RXL and BIB have an expense ratio of 0.95%.
Return for Risk
RXL vs. BIB — Risk / Return Rank
RXL
BIB
RXL vs. BIB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Health Care (RXL) and ProShares Ultra Nasdaq Biotechnology (BIB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| RXL | BIB | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.02 | 1.78 | -1.76 |
Sortino ratioReturn per unit of downside risk | 0.28 | 2.29 | -2.01 |
Omega ratioGain probability vs. loss probability | 1.03 | 1.29 | -0.26 |
Calmar ratioReturn relative to maximum drawdown | -0.10 | 3.35 | -3.45 |
Martin ratioReturn relative to average drawdown | -0.19 | 11.88 | -12.07 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| RXL | BIB | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.02 | 1.78 | -1.76 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.14 | 0.00 | +0.14 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.39 | 0.15 | +0.24 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.40 | 0.35 | +0.06 |
Correlation
The correlation between RXL and BIB is 0.77, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
RXL vs. BIB - Dividend Comparison
RXL's dividend yield for the trailing twelve months is around 1.61%, more than BIB's 0.60% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
RXL ProShares Ultra Health Care | 1.61% | 1.43% | 1.22% | 0.18% | 0.32% | 0.10% | 0.15% | 0.27% | 0.32% | 0.11% | 0.12% | 0.93% |
BIB ProShares Ultra Nasdaq Biotechnology | 0.60% | 0.77% | 1.69% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
RXL vs. BIB - Drawdown Comparison
The maximum RXL drawdown since its inception was -67.70%, roughly equal to the maximum BIB drawdown of -67.24%. Use the drawdown chart below to compare losses from any high point for RXL and BIB.
Loading graphics...
Drawdown Indicators
| RXL | BIB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.70% | -67.24% | -0.46% |
Max Drawdown (1Y)Largest decline over 1 year | -22.73% | -21.73% | -1.00% |
Max Drawdown (5Y)Largest decline over 5 years | -36.08% | -65.86% | +29.78% |
Max Drawdown (10Y)Largest decline over 10 years | -51.00% | -66.20% | +15.20% |
Current DrawdownCurrent decline from peak | -17.90% | -23.89% | +5.99% |
Average DrawdownAverage peak-to-trough decline | -15.82% | -32.84% | +17.02% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.68% | 6.13% | +5.55% |
Volatility
RXL vs. BIB - Volatility Comparison
The current volatility for ProShares Ultra Health Care (RXL) is 9.47%, while ProShares Ultra Nasdaq Biotechnology (BIB) has a volatility of 16.73%. This indicates that RXL experiences smaller price fluctuations and is considered to be less risky than BIB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| RXL | BIB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.47% | 16.73% | -7.26% |
Volatility (6M)Calculated over the trailing 6-month period | 20.60% | 28.82% | -8.22% |
Volatility (1Y)Calculated over the trailing 1-year period | 35.51% | 47.20% | -11.69% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 29.34% | 43.32% | -13.98% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 33.19% | 46.77% | -13.58% |